SAN JOSE, Calif., Oct. 15, 2025 /PRNewswire/ -- At 2025 OCP Global Summit (Booth #A55), MSI, a leading global provider of high-performance server solutions, highlights the ORv3 21" 44OU rack, OCP DC-MHS platforms, and GPU servers built on NVIDIA MGX module architecture, accelerated by the latest NVIDIA Hopper GPUs and NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs. These solutions target hyperscale, colocation, and AI deployments, delivering the scalability and efficiency required for next-gen data centers. On Oct 16, MSI Product Marketing Manager Chris Andrada will also present an Expo Hall session titled "Pioneering the Modern Datacenter with DC-MHS Architecture."
"Our focus is on helping datacenter operators bridge the gap between rapidly advancing compute technologies and real-world deployment at scale. By integrating rack-level design with open standards and GPU acceleration, we aim to simplify adoption, reduce complexity, and give the industry a stronger foundation to support the next wave of AI and data-driven applications," said Danny Hsu, General Manager of MSI's Enterprise Platform Solutions.
ORv3 Rack-Scale Integration
MSI's ORv3 21" 44OU Rack comes fully validated with integrated power, thermal, and networking, reducing engineering effort and deployment time for hyperscale environments. With 16 dual-node servers, centralized 48V power shelves, and all front-facing I/O, operators gain more space for CPUs, memory, and storage while keeping airflow clear for efficient cooling.
The CD281-S4051-X2 2OU 2-node DC-MHS server supports a single AMD EPYC™ 9005 CPU up to 500W TDP per node, each node with 12 DDR5 DIMM slots, 12 front E3.S PCIe 5.0 NVMe drives, and 2 PCIe 5.0 x16 slots for balanced compute, storage, and expansion. This combination provides dense performance for cloud and analytics, delivered in a rack system that can be deployed faster and serviced entirely from the cold aisle.
Standardization with OCP DC-MHS Server & Motherboards
MSI's DC-MHS portfolio offers standardized server and HPM designs across Intel® Xeon® 6 and AMD EPYC 9005 processors for CSPs and hyperscale data centers. With standardized DC-SCM modules, these platforms reduce firmware effort and enable cross-vendor interoperability. Available in M-FLW, DNO-2, and DNO-4 form factors, they provide a consistent path to deploy next-gen CPUs without redesigning entire systems.
With support for DDR5 high-bandwidth memory, PCIe 5.0 for accelerators and I/O, and front-service NVMe bays, DC-MHS systems include options such as the CX270-S5062 2U Intel Xeon 6 platform or modular HPMs, which let customers align CPU power, memory density, and drive configurations to workload needs, from cloud clusters to hyperscale data centers. Intel HPMs include the D3071 (DNO-2 single-socket, 12 DIMM slots), D3061 (DNO-2 single-socket, 16 DIMM slots), and D3066 (DNO-4 single-socket, 16 DIMM slots). AMD HPMs include the D4051 (DNO-2 single-socket, 12 DIMM slots) and the D4056 (DNO-4 single-socket, 24 DIMM slots for higher capacity).
GPU Density with NVIDIA MGX
Built on the NVIDIA MGX modular architecture, MSI's GPU servers accelerate AI workloads across training, inference, and simulation with support for the latest NVIDIA Hopper GPUs and NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs.
- The CG481-S6053 (4U) integrates dual AMD EPYC 9005 CPUs, 8 FHFL PCIe 6.0 GPU slots, 24 DDR5 DIMM slots, and 8×400G Ethernet networking via NVIDIA ConnectX-8 SuperNICs, ideal for large-scale AI training clusters requiring maximum GPU density and bandwidth.
- The CG290-S3063 (2U) features a single Intel Xeon 6 CPU, 4 FHFL PCIe 5.0 GPU slots, and 16 DDR5 DIMM slots, providing a compact, efficient system optimized for AI inference and fine-tuning in space-sensitive environments.
Supporting Resources:
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Scaling Cloud and AI: MSI Highlights ORv3, DC-MHS, and MGX Solutions at 2025 OCP Global Summit
Australia's Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for registration via the provisional approval pathway.
Skyhawk delivered its application for provisional approval to the TGA today.
More than 115 patients are now on trial with SKY-0515.
BOSTON, March 3, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets for a series of challenging neurological diseases, announces that Australia's Therapeutic Goods Administration (TGA), responsible for the approval of the safety, quality, and efficacy of therapeutic goods, has determined that the Company's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for registration via the provisional approval pathway.
Skyhawk delivered its application submission to the TGA for provisional approval today.
"We are grateful that the TGA has determined SKY-0515 for the treatment of Huntington's disease meets its eligibility criteria for potential provisional approval," said Bill Haney, Skyhawk's CEO. "This represents an important first step toward what could be an accelerated path to approval in Australia and the world, offering the possibility of a disease modifying treatment for Huntington's patients who urgently need therapies for this devastating disease."
Treatment with SKY-0515 results in dose-dependent reductions of mHTT and PMS1, key drivers of Huntington's disease pathology. SKY-0515 has demonstrated excellent central nervous system exposure and been generally safe and well tolerated.
Patients receiving SKY-0515 in the Phase 1C trial of SKY-0515 demonstrate mean Composite Unified Huntington's Disease Rating Scale (cUHDRS) improvement from baseline. At nine months this improvement is +0.64 points in a pooled analysis, compared to expected worsening at nine months of cUHDRS in symptomatic patients of -0.73 points, based on propensity score weighting using Enroll-HD and TRACK-HD.
Huntington's disease is a rare, inherited and ultimately fatal neurodegenerative disorder that affects hundreds of thousands of people worldwide, including more than 40,000 symptomatic patients in the United States and over 2,000 Australians.1,2 There are currently no approved disease-modifying treatments which slow or halt disease progression.2
SKY-0515 is a small molecule RNA splicing modifier developed through Skyhawk's novel RNA-splicing platform, SKYSTAR®.
SKY-0515 is the first Skyhawk drug in clinical trials.
Skyhawk is developing additional novel drugs to treat neurological diseases for which there are no approved disease-modifying therapies.
About SKY-0515's Phase 1 Clinical Study
SKY-0515's Phase 1 clinical trial is a first-in-human trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKY-0515 in healthy volunteers and individuals with Huntington's disease (HD). The trial is separated into three parts. Parts A and B evaluated SKY-0515 in Healthy Volunteers. Part C is a double-blind placebo-controlled parallel design study of two dose levels of SKY-0515 and placebo in individuals with HD (HD-ISS Stage 1, 2, or mild Stage 3) for 84 days followed by a 12 month extension of active treatment where all participants receive either a low or high dose of SKY-0515 in a blinded fashion. The objectives of the study include evaluating mutant HTT protein and PMS1 mRNA. The first patients were dosed in SKY-0515's Part C in January 2025. Enrollment in Phase 1C of the SKY-0515 trial is now complete and the trial is ongoing.
About SKY-0515's Phase 2/3 FALCON-HD Clinical Study
FALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in 120 participants with Stage 2 and early Stage 3 HD across 12 sites in Australia and New Zealand, and 400 participants with Stage 2 and early Stage 3 HD in 40+ worldwide sites. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels or placebo, for a treatment period of at least 12 months. This trial aims to confirm the potential of SKY-0515 to modulate RNA splicing and reduce mHTT and PMS1 proteins, which are implicated in the pathology of Huntington's disease, and to assess the efficacy of the SKY-0515 in affecting the rate of Huntington's disease progression. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at ClinicalTrials.gov and www.FALCON-HD.com.
About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company which uses its proprietary platform, SKYSTAR®, to discover and develop small molecule RNA modulating therapies for the world's most intractable diseases. For more information visit www.skyhawktx.com.
Skyhawk Contact
Maura McCarthy
Head of Corporate Development
maura@skyhawktx.com
References
Photo - https://mma.prnasia.com/media2/2923501/Skyhawk_Therapeutics__Phase_1_Part_C_patient_cohort_cUHDRS.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
